These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 12729639)

  • 1. 2,4-disubstituted pyrimidines: a novel class of KDR kinase inhibitors.
    Manley PJ; Balitza AE; Bilodeau MT; Coll KE; Hartman GD; McFall RC; Rickert KW; Rodman LD; Thomas KA
    Bioorg Med Chem Lett; 2003 May; 13(10):1673-7. PubMed ID: 12729639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and initial SAR studies of 3,6-disubstituted pyrazolo[1,5-a]pyrimidines: a new class of KDR kinase inhibitors.
    Fraley ME; Hoffman WF; Rubino RS; Hungate RW; Tebben AJ; Rutledge RZ; McFall RC; Huckle WR; Kendall RL; Coll KE; Thomas KA
    Bioorg Med Chem Lett; 2002 Oct; 12(19):2767-70. PubMed ID: 12217372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors: improvements in physical properties enhance cellular activity and pharmacokinetics.
    Fraley ME; Rubino RS; Hoffman WF; Hambaugh SR; Arrington KL; Hungate RW; Bilodeau MT; Tebben AJ; Rutledge RZ; Kendall RL; McFall RC; Huckle WR; Coll KE; Thomas KA
    Bioorg Med Chem Lett; 2002 Dec; 12(24):3537-41. PubMed ID: 12443771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiangiogenic and antitumor agents. Design, synthesis, and evaluation of novel 2-amino-4-(3-bromoanilino)-6-benzylsubstituted pyrrolo[2,3-d]pyrimidines as inhibitors of receptor tyrosine kinases.
    Gangjee A; Yang J; Ihnat MA; Kamat S
    Bioorg Med Chem; 2003 Nov; 11(23):5155-70. PubMed ID: 14604679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.
    Hennequin LF; Stokes ES; Thomas AP; Johnstone C; Plé PA; Ogilvie DJ; Dukes M; Wedge SR; Kendrew J; Curwen JO
    J Med Chem; 2002 Mar; 45(6):1300-12. PubMed ID: 11881999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New 2,4-disubstituted-2-thiopyrimidines as VEGFR-2 inhibitors: Design, synthesis, and biological evaluation.
    Abdel-Mohsen HT; Girgis AS; Mahmoud AEE; Ali MM; El Diwani HI
    Arch Pharm (Weinheim); 2019 Nov; 352(11):e1900089. PubMed ID: 31463965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New insights in the structure-activity relationships of 2-phenylamino-substituted benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors.
    Salerno S; García-Argáez AN; Barresi E; Taliani S; Simorini F; La Motta C; Amendola G; Tomassi S; Cosconati S; Novellino E; Da Settimo F; Marini AM; Via LD
    Eur J Med Chem; 2018 Apr; 150():446-456. PubMed ID: 29547832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The design, synthesis and biological evaluation of conformationally restricted 4-substituted-2,6-dimethylfuro[2,3-d]pyrimidines as multi-targeted receptor tyrosine kinase and microtubule inhibitors as potential antitumor agents.
    Zhang X; Raghavan S; Ihnat M; Hamel E; Zammiello C; Bastian A; Mooberry SL; Gangjee A
    Bioorg Med Chem; 2015 May; 23(10):2408-23. PubMed ID: 25882519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and evaluation of 3-(5-thien-3-ylpyridin-3-yl)-1H-indoles as a novel class of KDR kinase inhibitors.
    Fraley ME; Arrington KL; Hambaugh SR; Hoffman WF; Cunningham AM; Young MB; Hungate RW; Tebben AJ; Rutledge RZ; Kendall RL; Huckle WR; McFall RC; Coll KE; Thomas KA
    Bioorg Med Chem Lett; 2003 Sep; 13(18):2973-6. PubMed ID: 12941314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The synthesis and SAR of 2-amino-pyrrolo[2,3-d]pyrimidines: a new class of Aurora-A kinase inhibitors.
    Moriarty KJ; Koblish HK; Garrabrant T; Maisuria J; Khalil E; Ali F; Petrounia IP; Crysler CS; Maroney AC; Johnson DL; Galemmo RA
    Bioorg Med Chem Lett; 2006 Nov; 16(22):5778-83. PubMed ID: 16949284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-Hydroxy-4,6-diamino-[1,3,5]triazines: a novel class of VEGF-R2 (KDR) tyrosine kinase inhibitors.
    Baindur N; Chadha N; Brandt BM; Asgari D; Patch RJ; Schalk-Hihi C; Carver TE; Petrounia IP; Baumann CA; Ott H; Manthey C; Springer BA; Player MR
    J Med Chem; 2005 Mar; 48(6):1717-20. PubMed ID: 15771417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and SAR of thienopyrimidine and thienopyridine inhibitors of VEGFR-2 kinase activity.
    Munchhof MJ; Beebe JS; Casavant JM; Cooper BA; Doty JL; Higdon RC; Hillerman SM; Soderstrom CI; Knauth EA; Marx MA; Rossi AM; Sobolov SB; Sun J
    Bioorg Med Chem Lett; 2004 Jan; 14(1):21-4. PubMed ID: 14684289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo.
    Yang LL; Li GB; Ma S; Zou C; Zhou S; Sun QZ; Cheng C; Chen X; Wang LJ; Feng S; Li LL; Yang SY
    J Med Chem; 2013 Feb; 56(4):1641-55. PubMed ID: 23362959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2.
    Salerno S; Marini AM; Fornaciari G; Simorini F; La Motta C; Taliani S; Sartini S; Da Settimo F; García-Argáez AN; Gia O; Cosconati S; Novellino E; D'Ocon P; Fioravanti A; Orlandi P; Bocci G; Dalla Via L
    Eur J Med Chem; 2015 Oct; 103():29-43. PubMed ID: 26318056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4-Aryl-5-cyano-2-aminopyrimidines as VEGF-R2 inhibitors: synthesis and biological evaluation.
    Hughes TV; Emanuel SL; Beck AK; Wetter SK; Connolly PJ; Karnachi P; Reuman M; Seraj J; Fuentes-Pesquera AR; Gruninger RH; Middleton SA; Lin R; Davis JM; Moffat DF
    Bioorg Med Chem Lett; 2007 Jun; 17(12):3266-70. PubMed ID: 17481894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a new chemical class of potent angiogenesis inhibitors based on conformational considerations and database searching.
    Furet P; Bold G; Hofmann F; Manley P; Meyer T; Altmann KH
    Bioorg Med Chem Lett; 2003 Sep; 13(18):2967-71. PubMed ID: 12941313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055.
    Gingrich DE; Reddy DR; Iqbal MA; Singh J; Aimone LD; Angeles TS; Albom M; Yang S; Ator MA; Meyer SL; Robinson C; Ruggeri BA; Dionne CA; Vaught JL; Mallamo JP; Hudkins RL
    J Med Chem; 2003 Dec; 46(25):5375-88. PubMed ID: 14640546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single agents with designed combination chemotherapy potential: synthesis and evaluation of substituted pyrimido[4,5-b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents.
    Gangjee A; Zaware N; Raghavan S; Ihnat M; Shenoy S; Kisliuk RL
    J Med Chem; 2010 Feb; 53(4):1563-78. PubMed ID: 20092323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships.
    Boyer SJ
    Curr Top Med Chem; 2002 Sep; 2(9):973-1000. PubMed ID: 12171566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.